Targeting hypoxia-inducible factor-1 alpha suppresses Helicobacter pylori -induced gastric injury via attenuation of both cag -mediated microbial virulence and proinflammatory host responses.

Helicobacter pylori -induced inflammation is the strongest known risk factor for gastric adenocarcinoma. Hypoxia-inducible factor-1 (HIF-1α) is a key transcriptional regulator of immunity and carcinogenesis. To examine the role of this mediator within the context of H. pylori -induced injury, we first demonstrated that HIF-1α levels were significantly increased in parallel with the severity of gastric lesions in humans. In interventional studies targeting HIF-1α, H. pylori -infected mice were treated ± dimethyloxalylglycine (DMOG), a prolyl hydroxylase inhibitor that stabilizes HIF-1α. H. pylori significantly increased proinflammatory chemokines/cytokines and inflammation in vehicle-treated mice; however, this was significantly attenuated in DMOG-treated mice. DMOG treatment also significantly decreased function of the H. pylori type IV secretion system (T4SS) in vivo and significantly reduced T4SS-mediated NF-κB activation and IL-8 induction in vitro . These results suggest that prolyl hydroxylase inhibition protects against H. pylori -mediated pathologic responses, and is mediated, in part, via attenuation of H. pylori cag -mediated virulence and suppression of host proinflammatory responses.